Breaking AI & Tech News Analyzed

Iran's judiciary announced on Monday that the assets of Zahra Ghanbari, captain of the Iranian women's football team, have been released. This decision comes after Ghanbari initially sought asylum in Australia, only to later withdraw her claim and return to Iran. Ghanbari was among a group of six players and one backroom staff member who sought asylum in Australia in March, following their participation in the Women's Asian Cup. The move sparked controversy, particularly as it coincided with the escalating conflict between Iran, Israel, and the United States. Upon their return to Iran, Ghanbari and the other players were greeted as heroes in a special ceremony in central Tehran on March 19. The Iranian judiciary's decision to release Ghanbari's assets was made after she declared her innocence and changed her behavior. The release of Ghanbari's assets is significant, as Iranian authorities have been accused of pressuring athletes who compete abroad, threatening their families or seizing their property if they defect or make statements against the Islamic republic. Rights groups have repeatedly highlighted these concerns, citing cases where athletes have faced intimidation and coercion. In related developments, two Iranian women's footballers remain in Australia and have been training with the Brisbane Roar club. The controversy surrounding the team's asylum claims has unfolded against the backdrop of Iran's men's team preparing to play in the World Cup in the United States in June.

The National Gallery of Art's latest exhibition, 'Dear America: Artists Explore the American Experience', is a thought-provoking collection of over 100 works by 95 artists. This 'open letter to the nation' offers a multifaceted exploration of the American experience, delving into themes of land, community, and freedom.Upon entering the exhibition, visitors are immediately struck by the unconventional representations of iconic American symbols. The Statue of Liberty, for instance, is reimagined through the lens of South African photographer Zanele Muholi and a geometric screenprint by Roy Lichtenstein.The exhibition's curatorial approach is to create 'provocative conversations across centuries, disciplines and demographics.' E Carmen Ramos, the gallery's chief curatorial and conservation officer, notes that the show was 'years in the making' and showcases an 'embarrassment of riches' from the gallery's permanent collection of over 160,000 works.Structured around three core themes – land, community, and freedom – the exhibition presents a diverse array of works. These include Thomas Moran's idyllic watercolours of the American West juxtaposed with Thomas Hart Johnson's photographs of a landscape ravaged by coal mining and railroads. The exhibition also features poignant pieces such as Carrie Mae Weems's haunting silhouette and Gordon Parks's indelible 'American Gothic.'The show's second section, 'Community,' features Richard Avedon's massive 1976 commission 'The Family,' which comprises 69 stark, uniform portraits of the bicentennial era's political, media, and corporate elite. This is contrasted with John Wilson's tender sketches of his teenage children and their friends.The final act of the exhibition turns its lens to 'Freedom,' showcasing historical portraits of figures such as Frederick Douglass, Sojourner Truth, and George Washington, alongside powerful works by Kara Walker, Martha Rosler, and Faith Ringgold. As visitors exit, they are met with Robert Indiana's boldly coloured screenprint 'Liberty '76,' created for the 1976 bicentennial.Ramos reflects on the exhibition's significance, stating that it 'explores how artists in the United States have explored the American experience across different moments in time.' The exhibition will be on view in the National Gallery's West Building until 20 September.

Trump Media and Technology Group (TMTG), the parent company of the Truth Social platform, has formally withdrawn its defamation claim against The Guardian and two additional defendants. The suit had challenged a March 2023 Guardian report alleging that federal prosecutors were investigating $8 million in payments received by TMTG from entities with connections to Russian President Vladimir Putin. The dismissal was filed in the 12th Judicial Circuit Court in Sarasota County, Florida, on Friday. By withdrawing without prejudice, TMTG retains the option to re‑file the case at a future date. The Guardian’s original article said New York prosecutors opened a criminal inquiry into money wired to TMTG via the Caribbean by two parties that appeared to be partially controlled by an associate of a Putin ally. At the time, TMTG was preparing for a merger with Digital World Acquisition Corp (DWAC) that would have created a company valued at roughly $1.3 billion. Feeling vulnerable to accusations of receiving funds from a potentially hostile source, TMTG sued for libel, asserting that the Guardian’s statements were false and defamatory. In November, Judge Hunter W. Carroll dismissed the case against Guardian News and Media Ltd., Penske Media Corporation (owner of Variety), and former TMTG founder‑turned‑whistleblower Will Wilkerson, citing a failure to prove actual malice. Carroll, appointed by former Florida Governor Rick Scott, allowed TMTG to file an amended complaint, which the company did in January. A hearing was scheduled for the following Tuesday, but TMTG’s sudden withdrawal halted the proceedings. No reason was provided for the abrupt change. The Guardian has been contacted for comment. In April 2024, a lawyer for Trump sent The Guardian a letter calling its reporting “false” and a “hoax,” insisting that litigation would continue until the outlet retracted the story. Despite the legal tussle, there is no evidence that TMTG or its executives knowingly concealed the origin of the loans. No criminal charges have been brought against the company. Guardian News and Media responded, welcoming the voluntary dismissal and emphasizing that its reporting was based on meticulous fact‑checking, credible sources, and thorough documentation, while characterizing TMTG’s claims as meritless. The dismissal marks a rare retreat for Trump’s legal team, which has pursued an increasingly aggressive strategy against media outlets during his second presidential term, securing several high‑profile settlements with broadcasters such as ABC and CBS. Trump is currently pursuing a $15 billion defamation suit against The New York Times and a $10 billion claim against the BBC, alleging editorial manipulation of his speeches. Both cases have been described by the defendants as groundless and potentially chilling to press freedom. The Guardian’s investigation focused on two emergency loans TMTG received in December 2021 and February 2022, when the company faced a financial crisis after its merger with DWAC was delayed by SEC and FINRA investigations. Wire‑transfer records traced a $2 million payment through Paxum Bank, a Dominica‑registered institution, and a subsequent $6 million payment involving the ES Family Trust, whose trustee also served as a Paxum director. Federal prosecutors in the Southern District of New York examined Paxum Bank’s ownership, identifying a link to Anton Postolnikov, a relative of Aleksandr Smirnov, an associate of Putin.

Metabolic liver disease, or MASLD, is projected to affect 1.8 billion people worldwide by 2050, according to a recent study. This significant increase is primarily driven by rising obesity and blood sugar levels globally.MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most prevalent and rapidly growing liver conditions worldwide. The condition's prevalence has already seen a 143% increase in just three decades, from 500 million people in 1990 to 1.3 billion people in 2023.The study, published in the Lancet Gastroenterology & Hepatology journal, highlights that high blood sugar is the leading driver of MASLD-related health problems globally, followed by high BMI and smoking. These factors are strongly linked to type 2 diabetes and obesity.Regional disparities exist, with north Africa and the Middle East having disproportionately higher rates of MASLD. However, there have been sharp increases in the number of people affected in countries across the world, including the UK, Australia, and the United States.Despite the growing number of cases, the overall impact on health has remained stable, suggesting that advances in treatment and care are helping people live longer and healthier lives. However, the increasing number of cases still poses a risk of serious complications such as liver cirrhosis or cancer in the future.

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

Tucker Carlson, the former Fox News host, is set to launch his own publishing imprint, Tucker Carlson Books, in partnership with US-based publisher Skyhorse. The imprint aims to provide a platform for books that might otherwise be censored or shut down.Among the initial titles to be published are Russell Brand's How to Become a Christian in Seven Days, described as a "testimony and guide to a timeless, yet zeitgeist-capturing, grounded, yet psychedelic encounter with Christ." Brand is currently facing charges of rape, sexual assault, and indecent assault in the UK, to which he has pleaded not guilty.Another title set to be published is Milo Yiannopoulos's Ex Gay. Yiannopoulos, a controversial "alt-right" commentator, has previously been shunned by publishers due to his contentious views. His 2017 memoir, Dangerous, was canceled by Simon & Schuster after footage surfaced in which he made comments that appeared to condone sex between adult men and underage boys.Carlson, a former Trump supporter and promoter of right-wing conspiracy theories, was reportedly fired from Fox News in 2023. He soon launched his own media company, Tucker Carlson Network, and the imprint is being launched in partnership with this network.Skyhorse publisher Tony Lyons stated that the imprint will give "a platform to things that would, in many cases, be shut down, be censored, and be covered over by propaganda." Carlson emphasized that Lyons is "just looking for books that nobody else will publish."Skyhorse, which was launched in 2006, claims to be one of the fastest-growing independent book publishers in the US. Its previous publications include Woody Allen's memoir Apropos of Nothing and US Secretary of Health and anti-vaccine activist Robert F Kennedy Jr's The Real Anthony Fauci.

Chala Chala Nav Bala (Maze Baal, 1943) marks the debut of Asha Bhosle, who entered the film world at ten years old. Paired with her sister Lata Mangeshkar, her bright falsetto captures the youthful innocence of the Marathi romance, foreshadowing the emotive style that would define her career. Aaiye Meherbaan (Howrah Bridge, 1958) showcases Bhosle’s rise during Hindi cinema’s golden age, thanks to her partnership with composer O.P. Nayyar. The song’s sultry vibrato and lush orchestration set the tone for the film’s noir atmosphere, establishing her as a leading‑lady playback voice. Aao Huzoor Tumko (Kismat, 1968) became a chart‑topping hit, featuring intricate vocal runs over a flamenco‑style guitar. Bhosle’s lower‑register chorus broke the conventional shrillness of female playback, while her nuanced phrasing added depth to the on‑screen heroine’s drunken allure. Dum Maro Dum (Hare Rama, Hare Krishna, 1971) stands out as her most successful crossover, later sampled by Western rappers. The track, produced with R.D. Burman—her future husband—blends psychedelic Beatles‑inspired grooves with Hindi lyrics, demonstrating her ability to bridge Eastern and Western pop sensibilities. Piya Tu Ab To Aaja (Caravan, 1971) pushes the fusion further into jazz‑cabaret territory, with bold horn sections and cinematic guitar reverb. Bhosle’s breathy, suggestive delivery sparked controversy, yet the performance remains a masterclass in balancing sensuality with technical agility. Chura Liya Hai Tumne Jo Dil Ko (Yaadon Ki Baaraat, 1973) epitomises the “masala” film soundtrack, merging drama, romance, and crime. Over a gentle guitar backdrop, Bhosle’s tender humming conveys quiet longing, contrasting with the film’s high‑octane narrative. In Ankhon Ki Masti (Umrao Jaan, 1981) sees Bhoske venture into Urdu ghazals with composer Khayyam. Her lower, huskier timbre—adjusted a half‑step down—highlights her continued artistic experimentation even as she approached fifty. Bow Down Mister (1991) illustrates her early 1990s foray into international collaborations, lending wordless, soaring vocals to Boy George’s post‑Culture Club project. The track transforms into a rave‑infused anthem, underscoring Bhosle’s versatility across genres. Radha Kaise Na Jale (Lagaan, 2001) pairs Bhosle with a young A.R. Rahman, reaffirming her status as an elder stateswoman of Indian music. The duet with Udit Narayan blends tabla and flute with powerful vocal runs, marrying traditional Hindustani scales to contemporary film scoring. The Way You Dream (2002) features an unexpected partnership with REM frontman Michael Stipe on the 1 Giant Leap project. The eight‑minute piece weaves tabla rhythms, subtle guitar, and a dramatic breakbeat, proving that Bhosle’s voice can seamlessly inhabit New Age and electronic soundscapes.

Sam Neill, the veteran actor celebrated for his memorable performances on screen, is set to answer readers' questions in an upcoming interview with The Guardian. Neill's iconic roles include his portrayal in Jurassic Park, where he famously removes his sunglasses and gazes at a towering Brachiosaurus, a scene that has become etched in cinematic history.Born in Northern Ireland and raised in New Zealand, Neill's diverse filmography showcases his versatility as an actor. He has appeared in a range of films, from period dramas like My Brilliant Career to thrillers such as Dead Calm, which is set to be released in 4K later this year. His recent projects include Godzilla x Kong: Supernova, alongside Kaitlyn Dever and Matthew Modine.Neill's career has been marked by his ability to take on idiosyncratic, director-led projects, often playing characters with a unique blend of gruffness and warmth. His performances in Sweet Country and Rams have been particularly noted for their depth and nuance.In addition to his film work, Neill has also made headlines for his memoir, Did I Ever Tell You This?, in which he openly discusses his experience with stage-three blood cancer and his journey towards remission. When asked about his mortality, Neill expressed a pragmatic view, stating, “I’m not afraid to die, but it would annoy me”.Readers are invited to post their questions for Sam Neill by 6pm BST, Thursday 16 April, and The Guardian will publish his answers in their reader interview series. This provides a unique opportunity for fans to engage with one of cinema's most beloved actors and gain insight into his life and career.

Recent CDC data reveal a dramatic 1,200% increase in kratom‑related poisonings across the United States over the last ten years, with the most pronounced surge recorded in 2025. Researchers link this rise to the growing presence of 7‑hydroxymitragynine (7‑OH), a synthetically produced compound that mimics kratom’s effects but carries opioid‑like risks. Walter Prozialeck, pharmacology professor at Midwestern University, said the trend was expected, noting that the synthetic alkaloid has entered the market through energy drinks and other products since 2024. Christopher McCurdy of the University of Florida warned that marketing 7‑OH as “enhanced kratom” blurs the line for consumers, turning poison‑control calls into a conflated metric for both natural and synthetic products. By contrast, natural kratom (Mitragyna speciosa)—a Southeast Asian plant used for centuries as a pain reliever—has demonstrated a relatively favorable safety profile in animal and human studies. A 2018 statement from then‑HHS Secretary Brett Giroir rejected the DEA’s push to schedule kratom as a Schedule I substance, citing insufficient evidence of harm. Despite the scientific distinction, several states have moved to implement or propose blanket bans on all kratom products, prompting concern from clinicians and patient advocates. A recent user survey indicated that about 50% of respondents rely on kratom for chronic pain, while roughly 40% use it during addiction recovery. Personal testimonies underscore the plant’s therapeutic role. Jeff Maslan, a 68‑year‑old Californian with severe osteoarthritis, credits kratom with easing opioid withdrawal after multiple surgeries. Similarly, “Steven,” a disabled California resident, describes how kratom eliminated unbearable oxycodone withdrawal symptoms without producing the euphoric “warm fuzzy” feeling typical of opioids. Researchers emphasize that 7‑OH carries genuine opioid hazards, including addiction, severe withdrawal, and respiratory depression that can lead to fatal overdose. In animal models, 7‑OH demonstrated the same respiratory‑depression risk as classic opioids, whereas kratom’s primary alkaloid did not. Prozialeck and colleagues explain that kratom’s pharmacology is more nuanced: it partially activates opioid receptors while also engaging adrenergic and serotonin pathways, resembling a hybrid of a weak opioid and an SNRI‑type antidepressant. This multimodal action likely accounts for its lower euphoric potential and the reported boost in energy among users. Nevertheless, experts caution that kratom is not without risk. Fatal poisonings often involve co‑ingestion of potent opioids such as fentanyl, suggesting that some users may cycle between kratom and stronger substances, raising overdose danger due to reduced opioid tolerance. Additionally, heavy‑metal contamination has been detected in certain kratom batches, though the source—soil, processing, or storage—remains unclear. Given these complexities, the consensus among scholars like Austin Zamarripa (Johns Hopkins) is that natural kratom should remain accessible, while concentrated 7‑OH products merit stricter regulation. “These products may offer meaningful benefits to some individuals, and those benefits could be lost if access is restricted too broadly,” Zamarripa said, urging a differentiated policy approach. As the debate unfolds, patients like Steven worry that a sweeping ban would ignore the nuanced safety profile of the plant. “There’s corn on the cob, there’s high‑fructose corn syrup, there’s whiskey— all derived from corn but fundamentally different,” he remarked, highlighting the need for targeted, evidence‑based regulation rather than a one‑size‑fits‑all prohibition.